Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone

PURPOSE OF REVIEW: Giant cell tumor of bone (GCTB) is an uncommon benign primary bone tumor, consisting of receptor activator of nuclear factor kappa-B (RANK) expressing reactive osteoclast-like giant cells and neoplastic spindle-shaped cells. Denosumab was approved by FDA in 2013 and by EMA in 2014...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipplaa, Astrid, Dijkstra, Sander, Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
SARCOMAS: Edited by Jean-Yves Blay
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613724/
https://www.ncbi.nlm.nih.gov/pubmed/30844887
http://dx.doi.org/10.1097/CCO.0000000000000529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613724/
https://www.ncbi.nlm.nih.gov/pubmed/30844887
http://dx.doi.org/10.1097/CCO.0000000000000529

Ejemplares similares